COMMUNIQUÉS West-GlobeNewswire

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
30/09/2026
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting REVTORPYK [...]
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
30/09/2026
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million [...]
Vision Alive Max by Holistic Health Labs Features MaquiBright®, the Clinically Studied Maqui Berry Extract at the Research-Matched Dose
30/09/2026
New York, USA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Holistic Health Labs has announced that Vision Alive Max , its flagship eye-nutrition formula, features MaquiBright®, the branded, standardized maqui berry extract, at [...]
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
30/09/2026
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
30/09/2026
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
30/09/2026
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- [...]
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
30/09/2026
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced [...]
Ocugen to Participate in Upcoming Scientific Conferences
30/09/2026
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company [...]
AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
30/09/2026
Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB [...]
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
30/09/2026
Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in [...]
EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application
30/09/2026
The company is preparing to advance its drug candidate for complex perianal fistulas associated with Crohn’s disease into clinical development and aims to achieve first-in-human administration by the end of the first [...]
Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers
30/09/2026
HMBD-001, a differentiated anti-HER3 monoclonal antibody discovered and developed with Hummingbird Bioscience’s AI Molecular Medicine (AIMM) platform, has advanced into Phase II clinical development Recommended doses [...]
Italfarmaco Presents New Givinostat (Duvyzat®) Clinical Data Supporting Preservation of Upper Limb Function in Duchenne Muscular Dystrophy Patients at the 2026 World Muscle Society Congress
30/09/2026
New data suggest that givinostat treatment may slow the decline of upper limb function in boys with Duchenne muscular dystrophy compared with modelled external comparator disease trajectories derived from a single [...]
Terumo Neuro Signs Agreement to Acquire Arsenal Medical – Advancing Next-Generation Liquid Embolic Innovation for Treating Chronic Subdural Hematoma (cSDH)
30/09/2026
Proposed acquisition would add NeoCast™, an investigational technology designed for controlled delivery and predictable distal penetration, to Terumo Neuro’s neurovascular portfolio. Aliso Viejo, CA, Sept. 30, 2026 ( [...]
Orion Corporation completed share acquisitions
30/09/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 30 SEPTEMBER 2026 at 9.05 EEST Orion Corporation completed share acquisitions The share acquisitions [...]
Orion Corporation: Acquisition of own shares during week 40, 2026
30/09/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 30/09/2026 at 09.00 EEST Orion Corporation: Acquisition of own shares during week 40, 2026 The share buybacks form part of the share buyback [...]
AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
30/09/2026
Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB [...]
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
30/09/2026
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its [...]
Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study
30/09/2026
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without amplification of conventional CD4, CD8 or NK cell populations. [...]

Pages